Targets › APOA
1 program from 1 company in 1 trial: 1 Phase 3; Cardiovascular; next expected readout Mar 2031.
Open in Phaseline: the race on APOA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eli Lilly | Muvalaplin (LY3473329) Lipoprotein(a) biosynthesis inhibitor | APOA | Phase 3 | Elevated Lp(a) | Mar 2031 |
Elevated Lp(a) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.